Journal of Urgent Care Medicine

Newly Approved DHE Nasal Powder Treats Migraine

The Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder 5.2 mg for the acute treatment of migraine in adults with or without aura. The new product is currently the only DHE nasal powder available for this indication, according to a press release from manufacturer Satsuma. Clinical studies demonstrated that the formulation offers rapid absorption, quick attainment of high plasma DHE concentrations, and sustained levels over time. It was generally well tolerated both …

Older Migraine Drugs Work Better, Cost Less

Some older triptan drugs are better at relieving acute migraine pain than newer drugs, a systematic review and analysis of 137 randomized controlled trials suggests. As published in BMJ, researchers considered pain relief and freedom from pain at 2 hours in addition to sustained freedom from pain at 24 hours for nearly 90,000 participants who were randomized to one of 17 oral migraine drugs or placebo. All 17 drugs studied were more effective than placebo. …